TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00924560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 91-day Levonorgestrel Oral Contraceptive
Description: Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.~Take 1 tablet daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28-day Levonorgestrel Oral Contraceptive
Description: Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
Study: NCT01991444

Intervention type: OTHER
Intervention: TAVI
Description: no Intervention planned, Observation only
Study: NCT02858297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Description: Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Description: Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide
Description: Topical corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: Topical corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: Topical corticosteroid
Study: NCT01003314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine
Description: Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10\^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10\^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge
Description: Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
Study: NCT03466515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cells injection
Description: two surgical interventions as day-surgery, starting with liposuction from the abdomen (about 200-300 ml), and fistula tract debridement and closure of internal opening. The external opening is excised. About 30-40 ml fresh harvested patients own fatty tissue are then injected with large needle around the fistula from internal til external opening.The resting harvested fatty tissue will be sent to stem cells (Adipose Derived Regenrative Cells ADRCs) isolation, using Cytori Celusion system®. When the stem cells isolation is completed, 4ml concentrated stem cells ( contains around 20-40 millions cells ) will be injected around the prepared fistula tract, the same site where the fresh harvested fatty tissue injected before.
Study: NCT03580460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer delivered smoking cessation counseling
Description: 15 to 20 minute computer-delivered interactive smoking cessation counseling
Study: NCT02933190

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transvaginal surgery；UAE and D&C
Description: For cesarean scar pregnancy treatment
Study: NCT02378818

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Force task, preference task, discount task, learning task.
Description: Force task, preference task, discount task, learning task.
Study: NCT01667510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardio Mato
Description: Soft gel capsule for oral use

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gel capsule without test material
Study: NCT00117884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Study: NCT03061708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: mTOR inhibitor
Study: NCT03715465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 0.5 MG
Description: Melatonin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 MG
Description: Melatonin tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dim Light Melatonin Onset (salivary)
Description: Test to determine the time of melatonin onset in saliva under dim light conditions
Study: NCT01958567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Study: NCT04392414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent hyperimmune plasma
Description: Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-convalescent fresh frozen plasma (Standard plasma)
Description: Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
Study: NCT02665689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
Study: NCT00904124

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cellulose, alginate, guar gum
Description: 6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cellulose, alginate, guar gum
Description: 6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cellulose, alginate, guar gum
Description: 6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cellulose, alginate, guar gum
Description: 6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cellulose, alginate, guar gum
Description: 6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cellulose, alginate, guar gum
Description: 6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
Study: NCT05452382

Intervention type: PROCEDURE
Intervention: Partial colecctomy
Description: Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum

Intervention type: PROCEDURE
Intervention: Hemicolectomy
Description: Formal right hemicolectomy including terminal ileum, cecum, and ascending colon
Study: NCT03352440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral Palsy - Kinect
Description: Group with Cerebral Palsy that will perform the task on Kinect

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral Palsy - Touchscreen
Description: Group with Cerebral Palsy that will perform the task on Touchscreen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group - Kinect
Description: Group with typical development that will perform the task on Kinect

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group - Touchscreen
Description: Group with typical development that will perform the task on Touchscreen
Study: NCT00775567

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose powder
Description: 30g in 250ml water twice a day
Study: NCT06488196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing (MI) is a person-centered, goal-oriented psychotherapeutic intervention designed to enhance the recipient's motivation for and commitment to a target behavior or behavior change. MI's core action mechanisms include strengthening the recipient's change talk (e.g., assertions about desire and commitment toward the target behavior) and softening the recipient's sustain talk (e.g., statements about barriers). MI clinicians achieve these goals using specific micro-skills (e.g., reflective listening) that reflect MI's fundamental spirits (i.e. collaboration, acceptance, compassion, evocation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: TAU included the opportunity for mothers to meet with a NICU psychologist or psychology trainee at least once-per-week for supportive care.
Study: NCT03057444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SymbioIntest
Description: The intervention is 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
Study: NCT01320228

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Alli treatment plus placebo (rice flour)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capolac
Description: Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax fiber
Description: Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capolac+Flax fiber
Description: Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
Study: NCT01295333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation

Intervention type: DRUG
Group type: OTHER
Intervention: The initiation of LT4 as soon as the first biological signs of hypothyroidism.
Study: NCT00284115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait trainer
Description: Mechanical gait repetitive training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Physiotherapeutic conventional rehabilitation
Study: NCT04331899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1a
Description: Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection
Study: NCT04427085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound assessment of optic nerve sheath diameter
Description: Using ultrasonography, optic nerve sheath diameter is measured during perioperative period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of optic nerve sheath diameter
Description: Using ultrasonography, optic nerve sheath diameter is measured during perioperative period.
Study: NCT04721873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine-Topiramate
Description: Patients will be randomized to either once-daily, oral phentermine-topiramate 15-92mg or placebo, in a 1:1 fashion, for 22 weeks, with clinic visits with an obesity medicine specialist, for intensive counseling for diet and lifestyle intervention. All patients will be dose-titrated within the first 4 weeks, starting at phentermine-topiramate 3.75-23mg, or placebo. Dose titration will be performed as follows 3.75-23mg x 1 week --\> 7.5-46mg x 1 week --\> 11.25-69mg x 1 week --\> 15-92mg. Patients who experience side effects would undergo slower titration, and dose would be down-titrated and capped at highest tolerated dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, titrated as active intervention
Study: NCT03068962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: beetroot Juice
Description: Beetroot Juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: beetroot Juice
Description: Beetroot Juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buxton water
Description: natural mineral water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antiseptic mouthwash then beetroot juice
Description: Chlorhexidine glocunate
Study: NCT04704180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitation Tuchking Position
Description: The nurse placed the neonate in the facilitated tucking position by rolling up a sizeable sterile towel in a U-shape and covering it with covers available in the unit and then placed the neonate in a supine position. The physiological parameters at admission and in the 15th and 30th minutes of facilitated tucking were recorded. In the 30th minute of facilitated tucking, the researcher and the observer nurse completed the COMFORTneo simultaneously but separately. The neonate was in the facilitated tucking position until delivered to its mother. The researcher and the observer nurse had a full view of the neonate's face and body when completing the COMFORTneo, which took them about two minutes. After the neonate stabilized (within the first half an hour to an hour), it was delivered to its mother for breastfeeding based on specialist consent. The first breastfeeding was performed and completed the LATCH by researcher and the observer nurse.
Study: NCT01154413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive education of the doctor/nursing team on the protocol

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Intensive education of the doctor/nursing team on the protocol
Study: NCT02811705

Intervention type: OTHER
Intervention: Quality of life
Description: Quality of life

Intervention type: OTHER
Intervention: Quality of life
Description: Quality of life
Study: NCT00996840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-681323 Intravenous 3mg
Description: 3 mg SB-681323 Intravenous administration infused over 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-681323 Intravenous 7.5 mg
Description: 7.5 mg SB-681323 Intravenous administration infused over 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-681323 Intravenous 7.5mg
Description: 7.5 mg SB-681323 Intravenous administration infused over 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-681323 Intravenous 10mg
Description: 10 mg SB-681323 Intravenous administration infused over 24 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match intervention
Study: NCT02795988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-131
Description: IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-131
Description: IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
Description: Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
Description: Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
Description: Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
Study: NCT02494141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Dietary Supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00942409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISF35
Description: Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
Study: NCT00001703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: von Hippel-Lindau peptide vaccine
Description: 1000 micrograms administered subcutaneously every four weeks for a total of four vaccinations.
Study: NCT00485394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-551
Description: OT-551 0.3% ophthalmic solution, 2 drops 4 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-551
Description: OT-551 0.45% ophthalmic solution, 2 drops 4 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle placebo
Description: OT-551 0% ophthalmic solution, 2 drops 4 times daily
Study: NCT00117884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Study: NCT03167515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 074-6751 Lotion
Description: Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
Study: NCT02269657

Intervention type: DEVICE
Intervention: EOS® imaging system
Description: The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
Study: NCT01273350

Intervention type: DEVICE
Group type: OTHER
Intervention: Carotid PTA and stenting
Description: Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
Study: NCT03475303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early hospital discharge
Description: early hospital discharge at 8-12 hours for women undergone elective cesarean section
Study: NCT06308861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single administration Amg dose Group
Description: Orally, Amg tablet single administration
Study: NCT04027621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.